
Biogen's Salanersen Shows Promising Phase 1 Data in Spinal Muscular Atrophy
Newly announced interim data from a phase 1 study showed that treatment with salanersen (Biogen), an investigational antisense oligonucleotide administered once a year, was safe and led to slowing of neurodegeneration in patients with spinal muscular …